

Press release

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

- Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
- Macro Biologics, Inc. develops large molecule biologics which can alleviate or improve skin issues and prevent wound infections
- Beiersdorf also joins Macro Biologics, Inc. as an investor through its Oscar & Paul Corporate Venture Capital Unit

Hamburg, September 4, 2024 - Beiersdorf and Macro Biologics, Inc. have entered a multi-year partnership to collaborate on the development of biodegradable antimicrobial peptides with broad application possibilities in skin care and healthcare. At the same time, Beiersdorf joins Macro Biologics as an investor through its Oscar & Paul Corporate Venture Capital Unit. By bringing Macro Biologics' advanced technology in antimicrobial research into the skin care and healthcare ecosystem, Beiersdorf further underlines its ambition to continuously deliver transformative and sustainable innovations to its consumers.

The collaboration in this dynamic research field will focus on the utilization of Macro Biologics' highly effective antimicrobial "Amicidins" in Beiersdorf's innovative product and formula development. Amicidins are effective against a wide variety of bacteria, which means they can help to alleviate or improve skin conditions and are moreover designed for early, local application in the prevention of wound infections. The joint objective is to create highly effective, safe, and sustainable solutions for a variety of application areas across Beiersdorf's brand portfolio, primarily in dermatological skin care and healthcare.

"Through our collaboration with Macro Biologics, we further enhance Beiersdorf's innovation power in line with our 'Win with Care' strategy, as well as our ambition to continue to lead in Climate Care," emphasized Dr. Gitta Neufang, Corporate Senior Vice President Global R&D of Beiersdorf. "We are excited to have found an outstanding partner in this promising field of antimicrobial peptides, who shares our visionary innovation drive. We are eager to jointly bring Macro Biologics' advanced technology into the world of skin care and healthcare."

"We are very pleased to partner with Beiersdorf, a global powerhouse in skin care and healthcare," said Dr. Michael Bevilacqua, CEO and CSO of Macro Biologics. "For Macro, this collaboration is a perfect fit, both from a research and business perspective. Beiersdorf's deep expertise in product formulation, development, and commercialization will empower Amicidins to improve the lives of people in a variety of settings. This partnership is based on shared principles, as we both strive to create sustainable value for people and the environment."

Contact

Corporate Communications
Anke Schmidt
Tel.: +49 40 4909- 2001
E-mail: cc@beiersdorf.com

About Beiersdorf AG

Beiersdorf has stood for innovative skin care and pioneering skin research for over 140 years. The company headquartered in Hamburg, Germany, employs more than 22,000 people worldwide. In the fiscal year 2023 Beiersdorf generated sales of €9.5 billion and an operating result (EBIT margin excluding special factors) of €1.2 billion. Leading international brands such as NIVEA, Eucerin, La Prairie and Hansaplast are cherished by millions of people around the world every day. Renowned brands such as Aquaphor, Coppertone and Chantecaille complement the extensive portfolio in the Consumer Business Segment. Through its wholly owned subsidiary tesa SE, Beiersdorf is a globally leading manufacturer of technical adhesive tapes and provides self-adhesive solutions to industry, craft businesses, and consumers. Guided by the purpose 'Care Beyond Skin', Beiersdorf pursues an ambitious sustainability agenda with the goal of net zero emissions by 2045.

Additional information can be found at www.beiersdorf.com.



About Macro Biologics, Inc.

Macro Biologics, Inc., designs, patents, and produces large molecule biologics for innovative products across multiple industries - from healthcare to food & water to packaging. Amicidins, Macro Biologics' first class of proprietary macro biologics, are purpose-built for local application to vulnerable tissues to help prevent and treat life-threatening infections. Inspired by nature, they combine physical properties, like barrier formation, with broad and effective microbicidal activity against a wide variety of bacteria (including antibiotic-resistant strains), as well as *Candida* spp. Importantly, Amicidins are composed of amino acids and designed to be safe for people and the environment. The company's core principle is progress guided by nature. Macro Biologics is headquartered in Carlsbad, CA.

Additional information can be found at www.macrobiologics.com.

Contact

Corporate Communications
Anke Schmidt
Tel.: +49 40 4909- 2001
E-mail: cc@beiersdorf.com